May 2022 Joint Technical Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at https://member.ncpdp.org/work-groups.aspx?ID=wgmc.

Work Group 1 Telecommunication

Ballots adjudicated:

- **Ballot WG010088** – Enhancements to the Telecommunication Standard Implementation Guide Version F9 is considered a valid ballot having received 60+% of Consensus Group votes and 75+% approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG1 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:

- DERF 001881 was approved as modified.
- DERF 001892/ECL 000367 was recommended to MC to approve.
- DERF 001893/ECL 000368 was recommended to MC to approve as modified.
- DERF 001894/ECL 000369 was recommended to MC to approve as modified.
- DERF 001895/ECL 000370 was recommended to MC to approve.
- DERF 001896/ECL 000371 was recommended to MC to approve.

Task Groups:

- The **Telecommunication FAQ Task Group** reviewed three DERFs and four Frequently Asked Questions (FAQs). The Dispense As Written (DAW) and interchangeable biosimilars on claim submission question and answer and the route of administration question and answer were approved for inclusion in *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.
- The **P and C/WC Monitoring, Billing and Education Task Group** provided an update of legislative and regulatory developments from the last quarter.
- The **Coordination of Benefits (COB) Task Group** reviewed COB FAQ 73 – Tax and Regulatory Fee Guidance for Telecommunication VF6 and the examples guide for VF6 adding and updating examples as needed. The examples guide is under NCPDP internal review and will be published later this year. The task group also created COB FAQ 93 – Reject Code 70 “Product/Service Not Covered – Plan Benefit Exclusion” for non-Part D plans. The FAQ will be included in the COB FAQ document only.
- The **Information Reporting Problems Task Group** reviewed the Payer Sheet for N Transactions and recommends reject information not be included in the new payer sheet. The task group also reviewed the Wisconsin State Pharmaceutical Assistance Program (SPAP) memo drafted by WG9 COBC/BCRC Task Group.
- The **Definition of a Valid Prescriber Task Group** continued working on updates to the provider information in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates*. 
- The Benefit Integration Task Group completed their review of new fields needed for benefit synchronization and decided to create an examples document separate from the implementation guide. They continued to review related documents corresponding with the changes made for transaction format layout, examples document and implementation guide.
- The Clinical and Safety Edits Task Group continued their review of the DUR codes and presented DERF 001895/ECL 000370 to add a short description to Professional Service Code NM.
- The Telecommunication Agility Next Generation (TANG) Task Group continued reviewing grant work converting the Telecommunication Standard to JSON, began to plan training deliverables and confirmed no regulatory issues expected from a HIPAA-approved standard that includes extensibility.
- The Pharmacy Product Locator Task Group began a gap analysis between the product locator tool requirements and the existing Central Fill Product Inquiry and Response transactions in the Specialized Standard. WG1 voted to move the task group to WG11.
- The Pharmacy Services Billing Task Group evaluated accomplishments to date, discussed current pharmacist service billing needs and began drafting a white paper to provide recommendations on the use of the NCPDP Service Billing Transactions to address current gaps with pharmacist professional service claim billing and adjudication processes.
- The Point of Sale Rebate Review Task Group did not meet this quarter. WG1 voted to disband this task group.
- The Eligibility Verification Enhancements Task Group did not meet this quarter.
- The Expand Dollar Fields Task Group did not meet this quarter.
- The Post Adjudication Task Group did not meet this quarter.
- The Standardized Subrogation Task Group did not meet this quarter.

Other Reportables:
- **DSMO Change Requests**: There is no update on the status of the DSMO Change Request 1201 (New Version of the Batch Standard), 1202 (New Standard - Subrogation Implementation Guide for Batch Standard) and 1208 (New Version of the Telecommunication Standard). The Division of National Standards (DNS) is working on the Notice of Proposed Rulemaking (NPRM).
- **MC RTPB Standard Task Group**: A recap for this task group can be found in the WG1 download material.
- **MC REMS Workflow to Transaction Task Group, MC Prior Authorization Communication, Evaluation and Recommendations Task Group** and the **SNIP Committee**: Updates on the work of these task groups were given.

New Business:
- The **WG1 2021-2022 Accomplishments** presentation was given.

**Work Group 2 Product Identification**

DERFs Reviewed:
- DERF 001897 was approved.

Task Groups:
- The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
  - Reviewed five products via email and two during task group calls for verification of the package size or billing unit to list within the drug data compendia files.
  - The co-leads along with WG2 co-chairs and members of NCPDP staff participated in a virtual meeting with the Food and Drug Administration (FDA) to help answer their
questions about the implementation of the Unique Device Identifier (UDI) and how the Telecommunication Standard Version F6 affects the UDI.

- Created a new Billing Unit Standard (BUS) FAQ: What is the proper Billing Quantity and Billing Unit for products containing items not identified in the product insert and/or patient Instructions for Use? Updates to the billing unit and package size on products containing self-adhesive wraps, bandages and occlusive dressings will be completed by June 1, 2022.

- For January through March 2022, 2,127 new Structured Product Label (SPL) Billing Unit Index files were generated with four changed SPL Billing Unit Index files based on the files received by the FDA from the compendia. The compendia group has reconciled 10 of the 10 NDCs with discrepancies.

- Completed review of radiopharmaceutical products project. Coordination of billing unit change for those listed with a billing unit of ML updates was planned to be completed by June 1, 2022, but may be delayed. The task group created a notification letter to the impacted manufacturers that was pended back to the task group for additional work following a review by WG2.

- The Naming Standards for Drugs, Biologics and Biosimilars Task Group did not meet this quarter but will be following up on the monograph naming to address the FDA’s use of 4-letter suffixes and continue to monitor the official reports and actions from the FDA, United States Pharmacopeial Convention (USP), United States Adopted Names (USAN) and others on naming issues and make recommendations for standardize best practices as appropriate.

- The Outsourcing Facility Task Group will continue to work on the letter to the FDA to allow Outsourcing Facility (OSF) drugs to be listed on DailyMed following recommendations from the Standardization Committee.

Other Reportables:

- MC REMS Workflow to Transaction Task Group and MC Digital Therapeutics Task Group: Recaps for these task groups can be found in the WG2 download materials.

- MC NDC Scarcity Task Group: An update on the work of this task group was given.

New Business:

- The WG2 2021-2022 Accomplishments presentation was given.

- Jeff Shick of US Pharmacopeia provided information on USP Standardization of Compound Formulations and Compound Formulation Identifier (CFID) Identifiers.

Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards

Task Groups:

- The Manufacturer Rebate Standard Task Group discussed challenges with rebills and ways to develop best practices. The task group also discussed the management of retrospective errors in published versions of the Manufacturer Rebate Standard. Suzanne Kain gave a presentation about the task group discussion items.

- The Medical Rebate Standard Task Group did not meet this quarter.

New Business:

- The WG7 2021-2022 Accomplishments presentation was given.

Work Group 9 Government Programs

Ballots adjudicated:
• **WG090017** – Medicaid Pharmacy Encounters V10 is considered a valid ballot having received 60+% of Consensus Group votes and 75+% approval rating. Three comments to the ballot were received. WG9 reviewed and categorized the comments as persuasive and editorial. See Letter Ballot Comment spreadsheet for the ballot results on the WG9 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

• **WG090018** – Enhancements to the Prescription Drug Monitoring Programs (PDMP) Reporting Standard Implementation Guide V15 is considered a valid ballot having received 60+% of Consensus Group votes and 75+% approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG9 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

**DERFs/ECLs Reviewed:**
- DERF 001898/Emergency ECL 000372 was recommended to MC to approve.

**Task Groups:**
- The Prescription Drug Monitoring Programs Task Group continued monitoring state PMP activity and updated the State PMP Tracking Document, which was approved by WG9.
- The Government Programs Encounter Reporting Standard Task Group modified the task group scope statement, which was approved by WG9.
- The Coordination of Benefits Contractor (COBC)/Benefits Coordination and Recovery Center (BCRC) Task Group continued to work with RelayHealth, Wisconsin SPAP and CMS to develop a remediation plan for June 2022 to correct the Other Health Insurance (OHI) indicator and apply the N transactions correctly by creating a unique Bank Identification Number (BIN)/Processor Control Number (PCN) combination for qualified plans versus non-qualified plans. The task group also developed an FAQ and scheduled a webinar to be hosted by NCPDP on May 25, 2022.
  - The Chapter 14 Review Sub-Task Group completed the final review of Chapter 14. The document will be sent to CMS for review, approval and publication.
  - The Medicare Part D Section 111 Issues and Questions Sub-Task Group reviewed and discussed the Non-Group Health Plan (NGHP) Section 111 submission process and the impact it has on Medicare Part D plans. The sub-task group requested and received approval from WG9 to become a task group.
- The Hospice Task Group completed their review of the Hospice Election Status Transaction Processing Guidelines for Part D Plans and Valid Reject Codes for Part D Record of Hospice Status Transactions. Both documents were approved by WG9 for publication. The task group recommended additional modifications to the Part D Plan Hospice N Transactions Reject Report Guide. The task group presented DERF 001898/Emergency ECL 000372, which requests a new Reject Code specific to the Hospice Election Status Reporting Transaction (N2) scenario.
- The Medicare Financial Information Reporting (FIR) Task Group reviewed the FIR Payer Sheet v15, continued making updates to the FIR Implementation Guide, continued work on the FIR scenarios document and discussed possibilities of adding references for auditors to the implementation guide.
- The Medicare Part D Frequently Asked Questions Task Group reviewed the Medicare Part D FAQ Document Question 2.9 and collaborated with WG14 LTPAC Billing Issues Task Group to update the answer in the document. The task group also worked with WG45 Document Revisions Task Group to determine if the X12 835 Health Care Claim Payment/Advice can handle both positive and negative direct and indirect remuneration (DIR) at the claim and remittance level, if necessary.
• The **Medicare Prescription Drug Event (PDE) Task Group** discussed the CMS memo ‘Prescription Drug Event Guidance Related to Oral Antiviral Drugs for Treatment of COVID-19 that Receive U.S. Food and Drug Administration Emergency Use Authorization and are Procured by the U.S. Government’, determined the highest priority questions for resubmission to CMS, closed three open questions, worked with WG14 LTPAC Billing Issues Task Group to coordinate recommendations regarding the representation of short-cycle claims and collaborated with WG9 Medicare Part D FAQ Task Group to clarify the rules related to Medicaid Subrogation.

• The **Medicaid Frequently Asked Questions Task Group** did not meet this quarter.

• The **340B Task Group** did not meet this quarter.

• The **Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group** did not meet this quarter.

New Business:
• The **WG9 2021-2022 Accomplishments** presentation was given.

**Work Group 10 Professional Pharmacy Services**

Task Groups:
• The **MTM and Pharmacist Clinical Services Task Group** is waiting for the CMR Summary FHIR® wrapper until HL7® ballots the Multiple Chronic Condition (MCC) eCare Plan summary FHIR® implementation guide profile for patients and clinical team ([MCC eCare Plan efforts](#)). For the Beneficiary Level Report (BLR), the task group continues to work on a guidance document recommending a BLR standard for exchange between the provider of the Medication Therapy Management (MTM) services to the Medicare Advantage Prescription Drug (MAPD) plans or stand-alone Prescription Drug Plans (PDPs), including identification of NCPDP and/or HL7® standards.

• The **Pharmacogenomics Task Group** reviewed the Right Drug Now Act – a federal bill that was introduced ([https:// swalwell.house.gov/media-center/press-releases/swalwell-emmer-introduce-bipartisan-legislation-help-prevent-adverse](https:// swalwell.house.gov/media-center/press-releases/swalwell-emmer-introduce-bipartisan-legislation-help-prevent-adverse)). DERF 001894/ECL 000369, created by Xact Laboratories, was reviewed by **WG1 Telecommunication FAQ Task Group** and was approved as modified during WG1. The task group will continue to build and review pharmacogenomics (PGx) use cases.

• The **WG14/WG10 Standardized Medication Profile Task Group** – At the November 2021 Work Group meeting, the task group was assigned to review Project Development Form 56. The task group worked with the author of the project development form, Dr. Reed Gelzer, to clarify the project request. Dr. Gelzer rewrote the project request and resubmitted it for review during the February 2022 meeting. The project was approved by MC, approved by the Standardization Committee and Board of Trustees and assigned back to this task group. The task group is working to find a time to continue working on the project with Dr. Gelzer and his team.

• The **Identification of Social Determinants of Health Task Group** – The task group continued working on a white paper to address recommendations for social determinants of health in the pharmacy within NCPDP standards.

Other Reportables:
• **WG1 Pharmacy Services Billing Task Group** and **WG18 Specialty Requirements for ePrescribing Task Group**: Recaps for these task groups can be found in the WG10 download materials.

• **WG14 Consultant Pharmacist Interoperability Task Group**: An update on the work of this task group was given.

Industry Updates:
• There was an update on USP Allergy Expert Panel presented by Donna Bohannon of USP.
• There was an update on USP Compound Preparations Expert Panel presented by Jeff Schick of USP.

New Business:
• DERF 001894/ECL 000369 was reviewed by Charlie Oltman. The DERF was approved as modified during WG1.
• The **WG10 2021-2022 Accomplishments** presentation was given.

**Work Group 11 ePrescribing & Related Transactions**

**Ballots Adjudicated**

• **WG110088** – Enhancements to the SCRIPT Standard Implementation Guide, Specialized Implementation Guide and XML Implementation Guide is considered a valid ballot having received the required 60% of Consensus Group votes and 75%+ approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG11 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

• **WG110089** – Enhancements to the Formulary and Benefit Implementation Guide is considered a valid ballot having received the required 60% of Consensus Group votes and 75%+ approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG11 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

**DERFs Reviewed:**
• DERF 001872 was withdrawn.
• DERF 001882 was withdrawn.
• DERF 001899 was approved.
• DERF 001900 was approved as modified.
• DERF 001901 was pended.
• DERF 001902 was approved.
• DERF 001903 was approved as modified.

**Task Groups:**
• The **Dispensed Medication Reporting Task Group** did not meet this quarter.
• The **Formulary and Benefit Task Group** presented recommendations for a lighter version of the Formulary and Benefit Standard based on Version 3.0 with some of the added elements from Version 53 and higher. They also voted to send a letter to CMS asking to rescind the current request to name Version 53.
• The **Implementation of Structured Sig Task Group** completed the examples for medication administration for specific times such as 9:00 a.m. and 9:00 p.m. and 0900 and 2100.
• The **Pharmacy to Pharmacy Prescription Transfer Task Group** completed work on new RxTransfer examples for the changes to the transactions to allow push or pull options for the transfer. The task group will go on hiatus.
• **WG11 ePrescribing Regulatory Task Group** did not meet this quarter.
• The **Prior Authorization Workflow-to-Transactions Task Group** brought forth DERF 001899. They received updates around industry activity on prior authorization and submitted comments for the Office of the National Coordinator (ONC) for Health IT and Health and Human Services (HHS) request for information around Electronic Prior Authorization Standards Implementation.
• The SCRIPT Implementation Recommendations Task Group brought forth DERFs 001882 and 0019101. They also received approval for several additions and modification to the SCRIPT Implementation Recommendations document.
  o The RxChange Guidance Review Sub-Task Group brought forth DERF 001872.
• The XML Task Group brought forth DERF 001900 and reviewed and provided recommendations on all submitted DERFs impacting the schema.
• The WG14/WG11 LTPAC ePrescribing Task Group brought forth DERF 001902. They also received approval for a new FAQ to be included in the SCRIPT Implementation Recommendations document.

Other Reportables:
• SCRIPT Version 2017071 NSC-11 certified members were recognized.
• MC REMS Workflow to Transaction Task Group: An update on the work of this task group was given.

New Business:
• A request was made and approved to move the WG1 Pharmacy Product Locator Task Group to WG11 contingent on the WG1 Telecommunication vote.
• The WG11 2021-2022 Accomplishments presentation was given.

Work Group 14 Long Term and Post Acute Care (LTPAC)

Old Business:
• Gary Schoettmer provided an LTPAC industry update.

Task Groups:
• The LTPAC Billing Issues Task Group began reviewing and updating guidance related to LTPAC Short Cycle and Submission Clarification Codes (SCC) to replace with LTPAC Dispense Frequency where applicable for Telecommunication Standard Version F6. The task group also reviewed a question from WG9 Medicare Part D FAQ Task Group regarding the update needed for reprocessing retroactive changes to LTC appropriate dispensed claims.
• The Consultant Pharmacist Interoperability Task Group decided to make additional updates to the current Consolidated Clinical Document Architecture (C-CDA) guidance document, “Consultant Pharmacist Consult Note v1.0: Guidance on the Use of the HL7® Clinical Document Architecture (CDA) Consolidated Templates for Clinical Notes R2.1 Consult Note”. The draft containing the FHIR® resource updates was approved by WG14 in February. The task group has since decided to expand the guidance document beyond LTC consultant pharmacists to be a “Pharmacist Consultation Note.” The HL7® Technical Steering Committee (TSC) approved the project scope statement, and HL7® review has commenced.
• The Long Term and Post Acute Care ePrescribing Task Group is beginning discussions on expanding FacilitySpecificHoursOfAdministrationTiming XML examples and continued discussion on expanding the LTPAC RxChange sub-categories. The task group created an FAQ to clarify that any LTPAC ePrescribing message can be configured as an open-ended order, e.g., RxRenewalRequest and Response, RxChangeRequest and Response, etc. The task group also reviewed DERF 001902 for modifications.
• The WG14/WG10 Standardized Medication Profile Task Group met with Dr. Reed Gelzer to discuss the New Project Development Form 56 (Create a specification for a defined data set fit for use in a Conformance – WGMC verifiable Reconciled Medication List (C-RML) application currently in development).

Other Reportables:
• **WG1 Eligibility Verification Task Group, WG9 Medicare Part D FAQ Task Group and WG9 Hospice Task Group**: Updates on the work of these task groups were given.

• **WG1 Clinical and Safety Edits Task Group**: A recap for this task group can be found in the WG14 download materials.

New Business:

• The **WG14 2021-2022 Accomplishments** presentation was given.

---

**Work Group 18 Specialty Pharmacy**

**DERFs Reviewed:**

• DERF 001904 was pended.

**Task Groups:**

• The **Specialty Pharmacy Data Exchange Task Group** continued working on the Performance Metrics Standard, including structure. Discussed possible beta implementation of Data Reporting Standard – a pharmacy partner is willing to pilot; but a manufacturer partner is needed. A project initiation notification was submitted to ANSI to notify the standard community of the development of a Performance Metrics Report Standard.

• The **Benefit Coverage Identification Task Group** completed and distributed a survey on specialty benefit coverage identification. The survey closed 2/28/2022. The final survey results were presented to the work group and are available in the WG18 May 2022 Supporting Documentation download.

• The **Patient Consent Task Group** worked toward supporting the two priority task group business cases within the NCPDP/HL7® Specialty Medication Enrollment FHIR® Implementation Guide (Unsolicited Consent and Consent Request/Response from the dispenser to the prescriber/clinic). The group completed draft implementation guide updates ([https://build.fhir.org/ig/HL7/fhir-specialty-rx](https://build.fhir.org/ig/HL7/fhir-specialty-rx)). Members of the task group participated in the HL7® FHIR® Connectathon track on May 3 and 4, 2022. The task group brought forth DERF 001904 for proposed implementation guide updates.

• The **Facilitation Access to Specialty Products Task Group** developed a recommendations paper providing information to manufacturers, prescribers, payers and pharmacies regarding hub services and limited distribution products. This recommendation paper was approved during the February Work Group meeting, pending revisions. The task group received additional feedback from the Standardization Committee, met to address these revisions and sent the recommendations paper back to the Standardization Committee for additional review.

• The **Specialty Requirements for ePrescribing Task Group** did not meet this quarter and is encouraging all task group members to attend the **WG18: Patient Consent Task Group**.

Other Reportables:

• **WG10 Identification of Social Determinants of Health Task Group, WG11 Prior Authorization Workflow-to-Transaction Task Group, MC REMS Workflow-to-Transaction Task Group** and **MC Real Time Prescription Benefit Standard Task Group**: Recaps for these task groups can be found in the WG18 download materials.

New Business:

• The **WG18 2021-2022 Accomplishments** presentation was given.

---

**Work Group 45 External Standards Assessment and Implementation Guidance**

**Old Business:**

• Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE and X12.
Task Groups:

- The **Pharmacy and/or Combination ID Card Task Group** presented an updated version of the *Pharmacy ID Card Fact Sheet* for approval and publication. Updates address the modifications made in versions 6 and 7 of the *Pharmacy and/or Combination ID Card Implementation Guide*.
- The **834/835 FAQ Task Group** did not meet this quarter.
- The **Document Revisions Task Group** did not meet this quarter, but the leads participated in a WG9 Medicare Part D FAQ Task Group call to share knowledge about DIR reporting on 835 files.
- The **DSMO Task Group** received no DSMO requests for review.

New Business:

- The **WG45 2021-2022 Accomplishments** presentation was given.

**MC Maintenance and Control – DERF Harmonization**

New Business:

- The following DERFs were highlighted to create awareness across multiple Work Groups that may have interest:
  - DERF 001889/ECL 000368
  - DERF 001898/Emergency ECL 000370
  - DERF 001901
  - DERF 001905/ECL 000373

**MC Maintenance and Control**

Ballots Adjudicated:

- **Ballot WGMC0011** – Enhancements to the Real-Time Prescription Benefit Standard Implementation Guide Version 13 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75% approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WGMC webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs: 14 new and 3 pended DERFs/ECLs were reviewed (see WG1, WG2, WG9, WG11 and WG18).

- DERF 001872 was withdrawn.
- DERF 001881 was approved as modified.
- DERF 001882 was withdrawn.
- DERF 001892/ECL 000367 was approved.
- DERF 001893/ECL 000368 was approved with modifications.
- DERF 001894/ECL 000369 was approved as modified.
- DERF 001895/ECL 000370 was approved.
- DERF 001896/ECL 000371 was approved.
- DERF 001897 was approved.
- DERF 001898/Emergency ECL 000372 was approved.
- DERF 001899 was approved.
- DERF 001900 was approved as modified.
- DERF 001901 was pended.
- DERF 001902 was approved.
- DERF 001903 was approved as modified.
- DERF 001904 was pended.
- DERF 001905/ECL 000373 was approved.
Old Business:

- Received updates for:
  - SNIP Committee
  - NCPDP Foundation
  - Project Development Form 000056 Reconciled Medication List
- Updates for the following were provided in the MC download materials:
  - HIPAA
  - DSMO Change Request System (CRS) Requests No. 1201, 1202 and 1208

Task Groups:

- The **Education/Legislation and Regulations Task Group** discussed the Version 3 draft of the 2022 *US Core Data for Interoperability* (USCDI) and submitted comments on topics applicable to NCPDP standards.
- The **Emergency Preparedness Task Group** updated the *NCPDP Emergency Preparedness Guidance Document* to add a FAQ about reimbursement for counseling without vaccine administration. The task group also decided the current wording in the guidance document is sufficient for the new SANOFI COVID-19 vaccine which is composed of a .25mL GSK component and a .25mL Sanofi component. The work group approved the updated document.
- The **X12 TR3 Comment Consolidation Task Group** is on hiatus and did not meet this quarter.
- The **Real Time Prescription Benefit Standard (RTPB) Task Group** drafted content for the RTPB Standard Implementation Recommendations document about the use of the alternative product segment for step therapy. The work group approved the updated document. The task group also decided to table the discussion about enhancing the standard for Medicare Part D accumulators and keep the coordination of benefits and compound use cases on hold in the parking lot.
  - The **Consumer and Provider RTPB Standards Monitoring Sub-Task Group** identified a potential gap between the RTPB Standard and the HL7® FHIR® CARIN Consumer Realtime Pharmacy Benefit Check Implementation Guide based on DERF 001891 from February 2022 Work Group. Jira tickets have been submitted in the HL7® system for review by the HL7® Pharmacy Work Group and the CARIN Alliance. The task group also initiated review of state legislation referencing consumer-facing RTPB.
  - The **Related RTPB Law Review Sub-Task Group** received updates on state legislation activity referencing provider facing RTPB. The task group also reviewed the step therapy content for the RTPB Standard Implementation Recommendations document as drafted by the parent task group.
- The **Digital Therapeutics Task Group** distributed a survey, with an initial April 30th deadline, to solicit feedback from the digital therapeutics (DTx) industry to help determine subsequent use cases to be addressed by the task group. The task group also discussed recent news articles and a MassHealth announcement related to digital therapeutics.
- The **NDC Scarcity Task Group** sent a letter with NCPDP recommendations to the FDA regarding the FDA’s intent to increase the labeler code length from five digits to six digits in advance of an anticipated NPRM release. The task group is currently assessing how to accommodate both the labeler code expansion and the retirement of the National Health Related Items Code (NHRIC) and determining any impact on other product identifiers.
- The **Definition and Use of Quantity and Day Supply Task Group** evaluated the implementation guides for non-XML standards to identify occurrences of days supply and quantity data elements that may need to be replaced and with which new discrete data element. The task group also began looking at situation-of-use language that may be needed in the Claim Billing and Information Reporting transactions of the Telecommunication Standard.
• The REMS Workflow to Transactions Task Group identified the SCRIPT RxChange transaction to be used for the Risk Evaluation and Mitigation Strategy (REMS) process and submitted DERF 001903 to request changes needed to support the use case. Work Group 11 reviewed and approved the DERF with modifications. The task group also discussed the CodeX REMS project.
• The NCPDP Standards Message Structure Harmonization Task Group distributed a survey to get input as to which standards may need to move or would benefit from moving to a different format. The task group began to review and analyze the survey results.
• The MC Prior Authorization Communication, Evaluation and Recommendations (PACER) Task Group developed their scope statement and presented it to work group for approval. MC approved the scope statement. The task group also walked through the flow for the Telecommunication P1 to P4 transactions.

New Business:
• The MC 2021-2022 Accomplishments presentation was given.
• The 2022-2023 Work Group Co-Chairs were announced.
• The 2D Barcode Task Group was reactivated and renamed the Barcode Utilization Task Group.